Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. 1995

A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
Cardiovasculair Onderzoeksinstituut Erasmus Universiteit Rotterdam, COEUR, Erasmus University, Netherlands.

BACKGROUND An insertion (I)/deletion (D) polymorphism of the angiotensin-converting enzyme (ACE) gene has been associated with differences in the plasma levels of ACE as well as with myocardial infarction, cardiomyopathy, left ventricular hypertrophy, and coronary artery disease. RESULTS We determined the cardiac ACE activity and the ACE genotype in 71 subjects who died of noncardiac disorders. Cardiac ACE activity was significantly higher (P < .01) in subjects with the ACE DD genotype (12.7 +/- 1.9 mU/g wet wt) compared with subjects with the ID (8.7 +/- 0.8 mU/g) and the II (9.1 +/- 1.0 mU/g) genotypes. This difference was independent of sex, age, and the time required for tissue collection. CONCLUSIONS Cardiac ACE activity is highest in subjects with the DD genotype. Elevated cardiac ACE activity in these subjects may result in increased cardiac angiotensin II levels, and this may be a mechanism underlying the reported association between the ACE deletion polymorphism and the increased risk for several cardiovascular disorders.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes

Related Publications

A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
December 1995, Journal of hypertension,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
January 2000, Circulation,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
December 1995, Diabetologia,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
March 1996, Stroke,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
January 1997, Acta clinica Belgica,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
December 1998, Journal of cardiovascular pharmacology,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
March 2008, BMC neurology,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
June 2008, Collegium antropologicum,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
August 2000, Circulation,
A H Danser, and M A Schalekamp, and W A Bax, and A M van den Brink, and P R Saxena, and G A Riegger, and H Schunkert
October 1999, Circulation,
Copied contents to your clipboard!